Get the Stockscreener App
6.86
0.07%
0.005
Accolade Inc stock is traded at $6.86, with a volume of 2.21M.
It is up +0.07% in the last 24 hours and up +96.56% over the past month.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
See More
Previous Close:
$6.855
Open:
$6.85
24h Volume:
2.21M
Relative Volume:
1.24
Market Cap:
$560.32M
Revenue:
$414.29M
Net Income/Loss:
$-99.81M
P/E Ratio:
-5.1393
EPS:
-1.3348
Net Cash Flow:
$-28.65M
1W Performance:
+0.00%
1M Performance:
+96.56%
6M Performance:
+73.67%
1Y Performance:
-48.15%
1-Day Range:
$6.85
$6.88
1-Week Range:
$6.82
$6.90
52-Week Range:
$3.08
$13.93
Accolade Inc Stock (ACCD) Company Profile
Name
Accolade Inc
Sector
Industry
Phone
610-834-2989
Address
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Compare ACCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACCD
Accolade Inc
|
6.86 | 560.32M | 414.29M | -99.81M | -28.65M | -1.3348 |
|
VEEV
Veeva Systems Inc
|
214.75 | 34.86B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
72.69 | 12.56B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
53.21 | 9.93B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
100.09 | 8.67B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.36 | 6.43B | 906.14M | -52.62M | 89.62M | -0.3621 |
Accolade Inc Stock (ACCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Reiterated | Needham | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-17-24 | Resumed | DA Davidson | Neutral |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| May-24-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Mar-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-09-23 | Downgrade | Jefferies | Buy → Hold |
| Feb-02-23 | Initiated | Raymond James | Outperform |
| Sep-08-22 | Resumed | Piper Sandler | Overweight |
| Sep-07-22 | Initiated | Truist | Buy |
| Aug-12-22 | Initiated | DA Davidson | Buy |
| May-02-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-29-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-29-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-29-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-11-22 | Initiated | Wells Fargo | Underweight |
| Apr-07-22 | Initiated | Guggenheim | Neutral |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-11-22 | Initiated | Goldman | Buy |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Sep-30-21 | Initiated | Berenberg | Buy |
| Sep-17-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-15-21 | Initiated | Needham | Buy |
| Mar-11-21 | Resumed | Goldman | Buy |
| Jan-15-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Initiated | Canaccord Genuity | Buy |
| Sep-22-20 | Initiated | DA Davidson | Buy |
| Jul-27-20 | Initiated | BofA Securities | Buy |
| Jul-27-20 | Initiated | Credit Suisse | Neutral |
| Jul-27-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | Morgan Stanley | Overweight |
| Jul-27-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Initiated | Robert W. Baird | Outperform |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
View All
Accolade Inc Stock (ACCD) Latest News
Halper Sadeh LLC Investigates Accolade, Inc. Sale to Transcarent for Fairness to Shareholders - HPBL
Investigation into Accolade Transaction with Transcarent: Potential Breach of Fiduciary Duty – Market - HPBL
Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL
Accolade Inc. (ACCD): Q3 2025 Earnings Preview and Stock Outlook – Market - HPBL
Accolade (ACCD) Stock Update: Analyst Ratings and Market Performance – Market - HPBL
Canaccord Genuity Downgrades Accolade (ACCD) - MSN
Accolade, Inc. (NASDAQ:ACCD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Accolade CEO Rajeev Singh sells common stock worth $3,721 By Investing.com - Investing.com Canada
Accolade CFO Stephen Barnes sells shares worth $1,953 - Investing.com India
Accolade CFO Stephen Barnes sells shares worth $1,953 By Investing.com - Investing.com Australia
Accolade CEO Rajeev Singh sells common stock worth $3,721 - Investing.com India
Accolade’s Merger Agreement with Transcarent Poses Strategic and Financial Risks - TipRanks
Catherine Wood's Strategic Adjustment in Accolade Inc Holdings - GuruFocus.com
Transcarent to acquire health advocacy and primary care company Accolade for $621m - MSN
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders - GlobeNewswire Inc.
Accolade: Fiscal Q3 Earnings Snapshot - The Washington Post
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerACCD, QTRX, AKYA, ESSA - Markets Insider
Accolade Q3 Earnings Assessment - Benzinga
Accolade, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2024 - Marketscreener.com
Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Accolade Inc. (ACCD) reports earnings - Quartz
Accolade (NASDAQ:ACCD) Stock Rating Lowered by William Blair - MarketBeat
Accolade (NASDAQ:ACCD) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
Raymond James Downgrades Accolade (ACCD) - MSN
Accolade to be Acquired, Taken Private by Transcarent in $621 Million Deal - MSN
Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat
Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy
Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals
Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat
Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance
How Accolade stock pulled off a 105% jump - Dataconomy
Stifel downgrades Accolade stock as competing bids deemed unlikely By Investing.com - Investing.com South Africa
Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com
Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com
Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com
Earnings Scheduled For January 9, 2025 - Benzinga
Transcarent to acquire health benefits platform Accolade for $621m - Healthcare Brew
Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com Australia
Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News
Seattle health care company to go private in $621 million acquisition deal - The Business Journals
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire
Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business
Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com
What's Going On With Accolade Stock Wednesday?Accolade (NASDAQ:ACCD) - Benzinga
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Accolade (NASDAQ:ACCD) Earns Market Perform Rating from Leerink Partners - MarketBeat
Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360
Accolade Inc Stock (ACCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.30%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):